Analyst Comment

Wrap-Up from the Deep Dive on Brain Cancer (GBM)

By Claus ThestrupCEO, Sweden

The stock closed at 11.43 DKK, down 0.4% on Friday.

CEO Ulrich Krasilnikoff began with a brief introduction to the company, followed by an engaging overview of the growth potential within Nuclear Medicine. He focused on the two key areas relevant to Curasight - treatment (uTREAT) and diagnostics (uTRACE). There is large interest from major pharmaceutical companies in this field, as highlighted by the increased M&A activity in the segment. Among these, CEO Ulrich Krasilnikoff mentioned Novartis’ acquisition of Mariana Oncology and Bristol-Myers Squibb’s (BMS) purchase of RayzeBio. The number of transactions in 2024 has already surpassed those in 2023. I refer to the attached slide for insights into market growth:

Curasight Markedet

CSO Andreas Kjær elaborated on the significance of the recently published uTRACE Phase 2 data in the EJNMMI Research journal. He also explained why Curasight has chosen GBM as the “proof-of-concept” candidate for the uTREAT study. For more details, read our latest update here:

Update regarding uTRACE phase 2 study

Curasight’s platform, based on the uPAR biomarker, is cancer-specific but not cancer-type specific. There is a clear correlation between the aggressiveness of the cancer and the amount of uPAR expressed.

Currently, approximately 50% of all cancer patients undergo radiation therapy, which often damages healthy tissue along with the tumor. Curasight’s theranostic platform offers a groundbreaking solution: it illuminates the tumor and its metastases and delivers targeted radiation from within, significantly reducing damage to healthy tissue.

Every year, there are 65,000 new cases of brain cancer in the EU and the US, 30,000 of which are high-grade gliomas—the primary market for Curasight. This disease primarily affects middle-aged adults and children, with a very high mortality rate. Current treatments rely mainly on radiation therapy and chemotherapy, with no significant innovations in this field for decades.

Below is a detailed timeline for the “Proof-of-Concept” uTREAT study:

Curasight Milestones

Finally the exercise period for Curasight’s TO1 warrants begins on November 21, 2024, and ends on December 5, 2024. The exercise price will be based on the VWAP20 with a 30% discount, within a range of DKK 11.50-15.55. Full utilization of the warrants could provide the company with up to DKK 57.5 million.

Listen to the full interview here: Deep Dive Brain cancer

Disclaimer: HC Andersen Capital receives payment from Curasight as part of a DigitalIR/Corporate Visibility and IR advisory agreement.
Claus Thestrup, November 18, 2024, at 09:05.

Login required

This content is only available for logged in users

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Read more on company page

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.